
Sol-Gel Investor Relations Material
Latest events

M&A Announcement
Sol-Gel

Q1 2025
23 May, 2025

Q3 2024
15 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sol-Gel Technologies Ltd
Access all reports
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. The company offers Phase 5 (clobex), a prescription liquid medication designed to selectively target specific classes of dendritic cells that initiate the immune response. Its smevetch is a topical compounded drug that contains tacrolimus and dexamethasone. The company was formerly known as Silex Platform Limited and changed its name to Sol-Gel Technologies Ltd. in June 2010. Sol-Gel Technologies Ltd. is based in London, the United Kingdom.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SLGL
Country
🇺🇸 United States